A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial

Tomer Hertz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Carolyn Williamson(National Health Laboratory Service), Daniel E. Geraghty(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Allan C. deCamp(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), N. Ngandu(University of Cape Town), Andrew Fioré-Gartland(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Nicole Frahm(Fred Hutch Cancer Center), P.B. Gilbert(Fred Hutch Cancer Center), C.A. Magaret(Fred Hutch Cancer Center), J. Kublin(Fred Hutch Cancer Center), Lawrence Corey(Fred Hutch Cancer Center), Hasan Ahmed(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Morgane Rolland(Henry M. Jackson Foundation), Ruwayhida Thebus(University of Cape Town), Brendan B. Larsen(University of Arizona), P.T. Edlefsen(Fred Hutch Cancer Center), M. Juliana McElrath(Fred Hutch Cancer Center), Murray G. Logan(University of Cape Town), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), JI Mullins(University of Washington), Cecelia Rademeyer(University of Cape Town), J. Marais(University of Cape Town), Glenda Gray(South African Medical Research Council)
Vaccine
October 18, 2016
Cited by 18


Related Papers